Understanding COVID-19 vaccine hesitancy

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(8), P. 1338 - 1339

Published: July 16, 2021

Language: Английский

---

COVID-19 Vaccine Hesitancy—A Scoping Review of Literature in High-Income Countries

Vaccines, Journal Year: 2021, Volume and Issue: 9(8), P. 900 - 900

Published: Aug. 13, 2021

Vaccine hesitancy forms a critical barrier to the uptake of COVID-19 vaccine in high-income countries or regions. This review aims summarize rates and its determinants A scoping was conducted Medline

Language: Английский

---

Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: July 1, 2022

The COVID-19 pandemic continues to impact daily life, including health system operations, despite the availability of vaccines that are effective in greatly reducing risks death and severe disease. Misperceptions vaccine safety, efficacy, risks, mistrust institutions responsible for vaccination campaigns have been reported as factors contributing hesitancy. This study investigated hesitancy globally June 2021. Nationally representative samples 1,000 individuals from 23 countries were surveyed. Data analyzed descriptively, weighted multivariable logistic regressions used explore associations with Here, we show more than three-fourths (75.2%) 23,000 respondents report acceptance, up 71.5% one year earlier. Across all countries, is associated a lack trust safety science, skepticism about its efficacy. Vaccine hesitant also highly resistant required proof vaccination; 31.7%, 20%, 15%, 14.8% approve requiring it access international travel, indoor activities, employment, public schools, respectively. For ongoing succeed improving coverage going forward, substantial challenges remain be overcome. These include increasing among those reporting lower confidence addition expanding low- middle-income countries.

Language: Английский

---

Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh

Science, Journal Year: 2022, Volume and Issue: 375(6577)

Published: Jan. 14, 2022

Persuading people to mask Even in places where it is obligatory, tend optimistically overstate their compliance for wearing. How then can we persuade more of the population at large act greater good? Abaluck et al . undertook a large, cluster-randomized trial Bangladesh involving hundreds thousands (although mostly men) over 2-month period. Colored masks various construction were handed out free charge, accompanied by range mask-wearing promotional activities inspired marketing research. Using grassroots network volunteers help conduct study and gather data, authors discovered that wearing averaged 13.3% villages no interventions took place but increased 42.3% in-person introduced. Villages reinforcement occurred also showed reduction reporting COVID-like illness, particularly high-risk individuals. —CA

Language: Английский

---

Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial

The Lancet Public Health, Journal Year: 2021, Volume and Issue: 6(6), P. e416 - e427

Published: May 13, 2021

Language: Английский

---

A Global Map of COVID-19 Vaccine Acceptance Rates per Country: An Updated Concise Narrative Review

Journal of Multidisciplinary Healthcare, Journal Year: 2022, Volume and Issue: Volume 15, P. 21 - 45

Published: Jan. 1, 2022

Abstract: The delay or refusal of vaccination, which defines vaccine hesitancy, is a major challenge to successful control COVID-19 epidemic. huge number publications addressing hesitancy necessitates periodic review provide concise summary acceptance rates worldwide. In the current narrative review, data on were retrieved from surveys in 114 countries/territories. East and Southern Africa (n = 9), highest rate was reported Ethiopia (92%), while lowest Zimbabwe (50%). West/Central 13), Niger (93%), Cameroon (15%). Asia Pacific 16), Nepal Vietnam (97%), Hong Kong (42%). Eastern Europe/Central 7), Montenegro (69%) Kazakhstan (64%), Russia (30%). Latin America Caribbean 20), Mexico (88%), Haiti (43%). Middle East/North (MENA, n 22), Tunisia Iraq (13%). Western/Central Europe North 27), Canada (91%) Norway (89%), Cyprus Portugal (35%). ≥ 60% seen 72/114 countries/territories, compared 42 countries/territories with between 13% 59%. phenomenon appeared more pronounced MENA, Central Asia, Africa. More studies are recommended Africa, address intentions general public get vaccination. Keywords: SARS-CoV-2, hesitance, resistance, rejection, willingness vaccinate, intention vaccinate

Language: Английский

---

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study

The Lancet Global Health, Journal Year: 2022, Volume and Issue: 10(6), P. e798 - e806

Published: April 23, 2022

Several countries have authorised or begun using a booster vaccine dose against COVID-19. Policy makers urgently need evidence of the effectiveness additional doses and its clinical spectrum for individuals with complete primary immunisation schedules, particularly in where schedule used inactivated SARS-CoV-2 vaccines.Using individual-level data, we evaluated prospective, observational, national-level cohort (aged ≥16 years) affiliated Fondo Nacional de Salud insurance programme Chile, to assess CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) boosters who had completed CoronaVac, compared unvaccinated individuals. Individuals administered vaccines from Feb 2, 2021, prespecified study end date Nov 10, were evaluated; excluded probable confirmed infection (RT-PCR antigen test) on before received at least one any COVID-19 2021. We estimated laboratory-confirmed symptomatic (symptomatic COVID-19) cases outcomes (hospitalisation, admission intensive care unit [ICU], death inverse probability-weighted stratified survival regression models estimate hazard ratios, accounting time-varying vaccination status adjusting relevant demographic, socioeconomic, confounders. change vaccinated associated series vaccine.11 174 257 eligible this study, among whom 4 127 546 (two doses) during period. 1 921 340 (46·5%) participants an booster, 2 019 260 (48·9%) 186 946 (4·5%) homologous CoronaVac. calculated adjusted (weighted Cox model) preventing 78·8% (95% CI 76·8-80·6) three-dose 96·5% (96·2-96·7) 93·2% (92·9-93·6) booster. The COVID-19-related hospitalisation, ICU admission, was 86·3% (83·7-88·5), 92·2% (88·7-94·6), 86·7% (80·5-91·0) 96·1% (95·3-96·9), 96·2% (94·6-97·3), 96·8% (93·9-98·3) 97·7% (97·3-98·0), 98·9% (98·5-99·2), 98·1% (97·3-98·6) booster.Our results suggest that heterologous provides high level protection COVID-19, including severe disease death. Heterologous showed higher than all outcomes, providing support mix-and-match approach.Agencia Investigación y Desarrollo through Científico Tecnológico, Millennium Science Initiative Program, Financiamiento Centros en Áreas Prioritarias.

Language: Английский

---

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Nature Reviews Clinical Oncology, Journal Year: 2022, Volume and Issue: 19(6), P. 385 - 401

Published: March 11, 2022

Language: Английский

---

A Scoping Review to Find Out Worldwide COVID-19 Vaccine Hesitancy and Its Underlying Determinants

Vaccines, Journal Year: 2021, Volume and Issue: 9(11), P. 1243 - 1243

Published: Oct. 25, 2021

The current crisis created by the coronavirus pandemic is impacting all facets of life. Coronavirus vaccines have been developed to prevent infection and fight pandemic. Since might be only way stop spread coronavirus. World Health Organization (WHO) has already approved several vaccines, many countries started vaccinating people. Misperceptions about persist despite evidence vaccine safety efficacy.To explore scientific literature find determinants for worldwide COVID-19 hesitancy as reported in literature.PRISMA Extension Scoping Reviews (PRISMA-ScR) guidelines were followed conduct a scoping review on willingness vaccinate. Several databases (e.g., MEDLINE, EMBASE, Google Scholar) searched relevant articles. Intervention- (i.e., vaccine) outcome- hesitancy) related terms used search these databases. was conducted 22 February 2021. Both forward backward reference lists checked further studies. Three reviewers worked independently select articles extract data from selected literature. Studies that quantitative survey measure acceptance included this review. extracted synthesized following narrative approach results represented graphically with appropriate figures tables.82 studies 882 identified our search. Sometimes, had performed same country, it observed high earlier decreased over time hope efficacy. People different varying percentages uptake (28-86.1%), (10-57.8%), refusal (0-24%). most common affecting vaccination intention include efficacy, side effects, mistrust healthcare, religious beliefs, trust information sources. Additionally, intentions are influenced demographic factors such age, gender, education, region.The underlying complex context-specific, across socio-demographic variables. Vaccine can also other health inequalities, socioeconomic disadvantages, systemic racism, level exposure misinformation online, some being more dominant certain than others. Therefore, strategies tailored cultures socio-psychological need reduce aid informed decision-making.

Language: Английский

---

Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 127, P. 102792 - 102792

Published: Jan. 1, 2022

Language: Английский

---